A preclinical study confirmed that in CRC models resistant to adagrasib, combining adagrasib with SOS1 or SHP2 inhibitors shows comparable efficacy, both surpassing the effectiveness of adagrasib combined with EGFR monoclonal antibodies 192. This evidence concerns the gene EGFR and colorectal carcinoma.